Severe asthma and bronchiectasis
Conditions
Interventions
None listed
Sponsors
No
Eligibility
Inclusion criteria
Inclusion criteria: - Dutch adult (>18 yr) included in RAPSODI - Received at least 1 dose of one of the anti-IL-5 treatments (mepolizumab, reslizumab, benralizumab). - Anti- IL-5 treatment was started before 1.9.2020 - Data on presence or absence of BE (reported comorbidity and CT-scan) are available
Exclusion criteria
Exclusion criteria: Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1a. Daily OCS dose Change in daily OCS dose between initiation (= the day of starting anti IL-5) and 1 year after start of anti-IL-5 therapy in OCS dependent patients with severe asthma and comorbid BE. 1b. Exacerbation rate Change in annualized exacerbation rate between 1 year before and 1 year after start of anti-IL-5 therapy in non-OCS dependent patients. Defined as: Percentage of patients with an exacerbation rate 0-1/= 2/>5 exacerbations/yr, 1 year before and 1 year after start of anti-IL-5 therapy. 2. Cumulative OCS dose Change in cumulative OCS use between 1 year before and 1 year after start of anti-IL-5 therapy in all patients with SEA and BE will be calculated as the sum of the amount of issued tablets multiplied by the strength (mg per tablet) in months -12 to 0 and months 0 to 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient reported outcome measures (PROMs) - 6-item Asthma Control Questionnaire score (ACQ-6) (22) - Asthma Quality of life questionnaire (AQLQ) (23) Asthma-related health care use | — |
Contacts
Public ContactSaar Van Nederveen-Bendien
HAGA Ziekenhuis
Outcome results
None listed